You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 3, March 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Case Reports and Small Case Series
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Retinal Toxic Effects Associated With Intravitreal Fomivirsen

Arch Ophthalmol. 2000;118:426-427.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Fomivirsen sodium is a new oligonucleotide drug that acts as an antisense compound to inhibit viral protein translation. It is given as an intravitreal injection weekly for 3 weeks and then every 3 weeks for maintenance.1 We report on retinal toxic effects associated with fomivirsen.

Report of a Case

A 41-year-old man with human immunodeficiency virus infection was seen with zone 2 cytomegalovirus (CMV) retinitis in his right eye on July 15, 1998. He had been enrolled in a phase III drug trial for fomivirsen sodium at a dose of 330 µg for treatment in his left eye. He was receiving 3000 mg a day of oral ganciclovir sodium to treat systemic CMV viremia (not part of study protocol). He was enrolled in the study, per protocol, at a dose of 165 µg for treatment in his right eye. The first injection was given on July 22, 1998, and was repeated on July 29 . . . [Full Text of this Article]


Comment
Haris I. Amin, MD
Rockford, Ill

Everett Ai, MD; H. Richard McDonald, MD; Robert N. Johnson, MD
San Francisco, Calif

Corresponding author: Haris I. Amin, MD, Northern Illinois Retina, 4855 E State St, Rockford, IL 61108 (e-mail: retinaguy@earthlink.net).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhibition of Human Cytomegalovirus Replication by Benzimidazole Nucleosides Involves Three Distinct Mechanisms
Evers et al.
Antimicrob. Agents Chemother. 2004;48:3918-3927.
ABSTRACT | FULL TEXT  

Role of a Mutation in Human Cytomegalovirus Gene UL104 in Resistance to Benzimidazole Ribonucleosides
Komazin et al.
J. Virol. 2004;78:710-715.
ABSTRACT | FULL TEXT  

Resistance of Human Cytomegalovirus to the Benzimidazole L-Ribonucleoside Maribavir Maps to UL27
Komazin et al.
J. Virol. 2003;77:11499-11506.
ABSTRACT | FULL TEXT  

Pigmentary Retinopathy Associated With Intravitreal Fomivirsen
Uwaydat and Li
Arch Ophthalmol 2002;120:854-857.
FULL TEXT  

Intravitreal Delivery of Oligonucleotides by Sterically Stabilized Liposomes
Bochot et al.
IOVS 2002;43:253-259.
ABSTRACT | FULL TEXT  

Retinal Toxic Effects Associated With Intravitreal Fomivirsen
Freedman
Arch Ophthalmol 2001;119:458-458.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.